

## LITERATURA

1. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. *J Hepatol* 2015; 62: 986–994.
2. Huelin P, Piano S, Solà E et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic-liver failure. *Clin Gastroenterol Hepatol* 2017; 15: 438–445.
3. Davenport A, Sheikh MF, Lamb E, et al. Acute kidney injury in acute-on chronic liver failure: where does hepatorenal syndrome fit? *Kidney International* 2017; 92: 1058–1070.
4. Solé C, Pole E, Solà E, et al. Hepatorenal syndrome in the era of acute kidney injury. *Liver International* 2018; 25: 1–11.
5. Belcher JM, Garcia-Tsao G, Sanyal AJ, et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. *Hepatology* 2013; 57: 753–762.
6. Fagundes C, Barreto R, Guevara M, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. *J Hepatol* 2013; 59: 474–481.
7. Bucsic T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. *Gastroenterology Report* 2017; 5: 127–137.
8. Krones E, Fickert P, Zitta S, et al. The chronic kidney disease epidemiology collaboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. *BMC Nephrol* 2015; 16: 1–10.
9. Barreto R, Elia C, Solà E, et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. *J Hepatol* 2014; 61: 35–42.
10. Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. *Hepatology* 2013; 57: 1–37.
11. Sola E, Kerbert AJ, Verspaget HW, et al. Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. *J Hepatol* 2016; 65: 914–920.
12. Kerbert AJ, Verbeke L, Chiang FW, et al. Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis. *PLoS One* 2015; 10: e0138264.
13. Adebayo D, Morabito V, Davenport A, et al. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. *Kidney Int* 2015; 87: 509–515.
14. Mandorfer M, Bota S, Schwabl P, et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. *Gastroenterology* 2014; 146: 1680–1690.
15. Theocharidou E, Krag A, Bendtsen F, et al. Cardiac dysfunction in cirrhosis – does adrenal function play a role? A hypothesis. *Liver Int* 2012; 32: 1327–1332.
16. Weichselbaum L, Gustot T. The Organs in Acute-on-Chronic Liver Failure. *Semin Liver Dis* 2016; 36: 174–180.
17. Shah N, Mohamed PE, Jover-cobos M et al. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. *Liver Int* 2013; 33: 398–409.
18. Gustot T, Durand F, Lebrec D, et al. Severe sepsis in cirrhosis. *Hepatology* 2009; 50: 2022–2033.
19. Bernardi M, Caraceni P, Navickis RJ, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. *Hepatology* 2012; 55: 1172–1181.
20. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *J Hepatol* 2018; 69: 406–460.
21. Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. *J Clin Exp Hepatol* 2014; 4: 302–311.
22. Afinogenova Y, Tapper EB. The efficacy and safety profile of albumin administration for patients with cirrhosis at high risk of hepatorenal syndrome is dose dependent. *Gastroenterol Rep (Oxf)* 2015; 3: 216–221.
23. Salerno F. Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. *BMC Gastroenterol* 2015; 55: 1–11.
24. Cavallin M, Piano S, Romano A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. *Hepatology* 2016; 63: 983–992.
25. Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. *J Hepatol* 2012; 56: 1293–1298.
26. Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. *Hepatology* 2015; 62: 567–574.
27. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatol* 2010; 53: 397–417.